2019 APPENDIX - CENTER OF NEUROLOGY TÜBINGEN - HERTIE-INSTITUT FÜR KLINISCHE HIRNFORSCHUNG
←
→
Transkription von Seiteninhalten
Wenn Ihr Browser die Seite nicht korrekt rendert, bitte, lesen Sie den Inhalt der Seite unten
center of neurology
tÜbIngen
Annual Report
2019
AppendIX
Content
Annual report 2019
Appendix
HIH boards
University Hospital of Neurology
Department of neurology with neurovascular
medicine and Neuro-oncology
Department of Neurology and Epileptology
Department of Neurodegenerative Diseases
Department of Cognitive Neurology
Department of Cellular Neurology
Independent Research Groups
HIH management
Publications and student training in 2019HIH
Boards
Supervisory Board Board of Trustees
Prof. Dr. Johannes Dichgans (chairman) Prof. Dr. Rudi Balling
Prof. Dr. Hans-Jochen Heinze Prof. Dr. Eckart Gundelfinger
Gabriele Sonntag Prof. Dr. Hans-Jochen Heinze (chairman)
Dr. h.c. Frank-J. Weise Prof. Dr. Herbert Jäckle
Prof. Dr. Ingeborg Krägeloh-Mann
Prof. Dr. Denise Manahan-Vaughan
Prof. Dr. Stefan Pulst
AdvIsory members
Prof. Dr. Ingo Authenrieth
Prof. Dr. Michael Bamberg
Prof. Dr. Johannes Dichgans
Prof. Dr. Pierluigi Nicotera
4Annual report 2019
Board of Directors Executive Board
Prof. Dr. Thomas Gasser (chairman) Prof. Dr. Thomas Gasser
Prof. Dr. Mathias Jucker Prof. Dr. Holger Lerche
Prof. Dr. Holger Lerche Dr. Astrid Proksch
Prof. Dr. Hans-Peter Thier
Prof. Dr. Ulf Ziemann
Administrative Director
Advisory members
Dr. Daniel Häufle Dr. Astrid Proksch
Prof. Dr. Philipp Kahle
Prof. Dr. Ulrike Naumann
Dr. Astrid Proksch
5University
Hospital of
Neurology
Clinical Staff wArd 42/43 Sina Westbomke
Emma Witte
Paul Alacron Stephanie Zanfardino
HeAd of nursIng servIces Diana Arko Shpend Zymeri
Luther Basa
Dr. Renate D. Fuhr Meike Besser
(Head of Nursing Services) Önder Bilen wArd 44
Irene Brady IntensIve cAre/
Susanne Fallscheer Mark Canoy stroke unIt
(Deputy Head of Nursing Services) Friedhelm Chmell
Olga Degraf Jerome Blancia
Marc-Sebastian Haug Michelle Dupke Karin Brunner
(Deputy Ward Manager, Ward 44) Annette Eisele Jane Buo
Rebecca Fais Ana-Maria Cheregi
Adriana Hurcikova Maria Flohr Adriana Digirolamo
(Division Manager, Ward 42/43/45) Karl Andrew Gallar Ebrar Döger
Joann Gallo Daniel Fuente Friend
Olga Krämer Alice Hoffmann Laura Gabriele
(Deputy Division Manager, Corinna Kalmbach-Ftits Eowyn Galvez
Ward 42/43/45) Petra Kaschowitz Susanne Grumann
Eva Kern Mustafa Hadzic
Annette Silber Gabriele Kern-Braun Frank Hauber
(Deputy Ward Manager, Ward 44) Franziska Lehmann Kathrin Haug
Renate Maier-Korneck Marc-Sebastian Haug
Gerda Weise Mary Catherine Odon Lea Heinzelmann
(Ward Manager, 44) Dorothe Pacholleck Sigrid Herter
Selina Palamatcu Elli Hofmann
Birgit Peter Yvonne Horz-Weger
Iris Sadowski Regina Johner
Sarah Schneider Victor Kadlec
Ulrike Schweizer Sandra Kästner
Gudrun Siegl Navdeep Kaur
Nicole Steiner Lothar Kunz
Birgit Weimar Christine Löffler
6Annual report 2019
Giusi Marchese Nursing Assistants Technicians
Christine Moosmann
Birgit Moryson Emad Abu Rinneh Sandra Berger (EMG)
Petra Nipprasch Abdulaziz Alofesh Fridos Bouraima (EEG)
Simone Ochieng Gesa Binzenbach Ingrid Braun
Gloria Peth Nadja Dendur (Neurocardiac Diagnostics)
Paul Pollehne Daniel Ganter Margarete Dengler (Nurse)
Christine Reuter Larissa Grillmayr Anke Deutsch (EP)
Jane Reutter Christian Hunger Evelyn Dubois (CFS Chemistry)
Claudia Romeikat Emese Jordan Maximilian Früchel
Thomas Rottmann Bassem Kiswani (Neurosonography)
Sibel Sari Steffen Klett Irina Köhnlein (Nurse)
Mirjam Schafer Gabriele Layla Renate Mahle
Cora Scheffold Katrin Letzgus (EEG, Neurosonography)
Simon Schippmann Mohammadhasan Mahmodi Veronika Serwotka
Christine Schmidt Susanne Oberländer (Nerve conduction)
Johann Schmuck Carolin Schmitt Elke Stransky (CSF Chemistry)
Lena Seelmann Frida Schubert Kathrin Vohrer (EEG, EP)
Brigitte Steinau Jonas Schug Julia Wittlinger
Tanja Striebich Merlin Stuber-Roselle (Neurosonography, EP)
Armin Teubert Rebekka Weitz Barbara Wörner (EEG)
Angelika Weber
Gerda Weise
Bettina Weisser ward assistants Secretaries
Eva Wener-Buck
Dieter Zeller Jana Otterbach Ina Baumeister
Ulrike Zimmermann Ann-Kathrin Schumacher Yvonne Brändle
Kübra Soysal Jutta Eymann
Dagmar Heller-Schmerold
Ward 45 Sabrina Kreiser
Case/Occupancy Isolde Marterer
Isaac Emwinghare Management Christine Riegraf
Karola Froehlich Susanne Stimmler
Werner Hansen Silvia Clement Diana Thomma
Michael Heymann Simone Dettinger Doris Wieder
Sevbenur Ibrahimova Christine Rebenschütz
Beate Kloster Michael Schütz-Böger
Jessica Kurz Isabel Utsch-Selinow Medical Documentation
Andrea Langmann
Kevin Lux Ute Behner
Alisa Mansour-Tokovic Horst Feuerbacher
Banu Sahin Natascha Jurawel
Juliana Salten Dr. Christina Lipski
Katrin Siedle (née Schindl) Martina Pabst
Anja Siegle Christina Tröger
Nadine Wolter
7Department of
Neurology with
Neurovascular
Medicine and
Neuro-Oncology
Clinical and Scientific Staff scIentIsts/resIdents
Dr. Ahmed Abdelhak
HeAd of tHe depArtment Dr. Yang Bai (since 10/2019)
Dr. David Baur
Prof. Dr. Ulf Ziemann Dr. Paolo Belardinelli
Dr. Til Ole Bergmann (5%)
Dr. Corinna Blum
group leAders/AttendIng pHysIcIAns Paula Bombach
Elisabeth Braun (neé Rexer) (until 04/2019)
Prof. Dr. Hermann Ackermann Jutta Dünschede
Dr. Rainer Greulich (Cardiologist) Dr. Mohamed Yasser Elnaggar
PD Dr. Markus Kowarik Dr. Irina Gepfner-Tuma (until 10/2019)
PD Dr. Markus Krumbholz Dr. Pedro Caldana Gordon
Prof. Dr. Arthur Melms (5%) Dr. Parameswari Govindarajan (until 06/2019)
Dr. Annerose Mengel Florian Härtig
Prof. Dr. Ulrike Naumann Prof. Dr. Ingo Hertrich
PD Dr. Sven Poli, MSc Dr. Sophie Hirsch
PD Dr. Mirjam Renovanz Dr. Marilin Koch
PD Dr. Johannes Rieger (5%) Valentin Kusch (since 02/2019)
Prof. Dr. Dr. Ghazaleh Tabatabai Anne Lieb (since 07/2019)
(Interdisciplinary Division of Neuro-Oncology) Dr. Daniel Merk
Dr. Johanna Metsomaa (since 08/2019)
Dr. Elisa Pichler
Dr. Khouloud Poli (neé Nafaa)
Dr. Hardy Richter
Dr. Christoph Ruschil
Dr. Jennifer Sartor
Dr. Natalie Schaworonkow (until 03/2019)
Patricia Schwarz
Vera Stadler
Maria-Ioanna Stefanou
Dr. Johannes Tünnerhoff
Dr. Brigitte Zrenner
Dr. Christoph Zrenner
8Annual report 2019
Technical staff/Administration Medical doctoral Students
Marcel Armbruster Abdullah Alekuzei (Supervisor Prof. Dr. Naumann)
Ulrike Baumann Dominik Baku (Supervisor PD Dr. Kowarik)
Dipl.-Ing. Rüdiger Berndt (Electronics, together Sinan Barus (Supervisor Prof. Dr. Ziemann)
with the Department of Cognitive Neurology) Hannes Becker (Supervisor Prof. Dr. Dr. Tabatabai)
Ingrid Braun (since 03/2019) Elina Brendle (Supervisor Prof. Dr. Dr. Tabatabai)
Evelyn Dubois Hui Chen (Supervisor PD Dr. Poli)
Sandra Gäßler-Kegelmann, MBA Elena Dangel (Supervisor Prof. Dr. Dr. Tabatabai)
Sarah Hendel Sara Dörre (Supervisor Prof. Dr. Ziemann)
Marion Jeric Juliane Ebert (Supervisor Prof. Dr. Dr. Tabatabai)
Anna Kempf Hermann Eckhardt (Supervisor Prof. Dr. Naumann)
Gabriele Kuebart Hulda Ewald (Supervisor Prof. Dr. Dr. Tabatabai)
Ivana Princip Ines Fachner (Supervisor Prof. Dr. Dr. Tabatabai)
Matthias Scholl Oliver Föhst (Supervisor Prof. Dr. Dr. Tabatabai)
Elke Stransky Katharina Hadaschik (Supervisor PD Dr. Poli)
Julia Zeller Mona Hirt (Supervisor Prof. Dr. Dr. Tabatabai)
Ilona Hoberg (Supervisor PD Dr. Bischof)
Yeho-Irae Kim (Supervisor Prof. Dr. Ziemann)
Master Students Franca Koenig (Supervisor Prof. Dr. Ziemann)
Natalya Korinetsko (Supervisor Prof. Dr. Dr. Tabatabai)
Maya Velardi (Supervisor Prof. Dr. Hertrich) Martin Korn (Supervisor Prof. Dr. Dr. Tabatabai)
Hannah Krämer (Supervisor Prof. Dr. Ziemann)
Felix Lennartz (Supervisor Prof. Dr. Dr. Tabatabai)
Professorship for Chen Liang (Supervisor Prof. Dr. Ziemann)
Neurorehabilitation Anne Lieb (Supervisor Prof. Dr. Ziemann)
Mirjam Lingel (Supervisor Prof. Dr. Ziemann)
Prof. Dr. Hermann Ackermann Adam Meder (Supervisor Prof. Dr. Ziemann)
Prof. Dr. Ingo Hertrich Hardy Richter (Supervisor PD Dr. Poli)
Francesca Russo (Supervisor PD Dr. Poli)
Martin Schippert (Supervisor Prof. Dr. Dr. Tabatabai)
PhD Students Leonie Schumacher (Supervisor Prof. Dr. Naumann)
Matthias Sonnleitner (Supervisor PD Dr. Poli)
Eric McDermott (Supervisor Prof. Dr. Ziemann) Charlotte Spencer (Supervisor PD Dr. Poli)
Debora Desideri (Supervisor Prof. Dr. Ziemann) Jakob Spogis (Supervisor Prof. Dr. Ziemann)
Maria Ermolova (Supervisor Prof. Dr. Ziemann) Marianna Stefanou (Supervisor Prof. Dr. Ziemann)
Lara Häusser (Supervisor Prof. Dr. Dr. Tabatabai) Miriam Thies (Supervisor Prof. Dr. Ziemann)
Desiree Blair Jovellar (Supervisor Prof. Dr. Ziemann) Dimitrios Vasilakis (Supervisor PD Dr. Poli)
Constanze Kemmerer (Supervisor: PD Dr. Kowarik) Xueyu Yang (Supervisor PD Dr. Poli)
Moritz Klawitter (Supervisor Prof. Dr. Naumann) Jan Zurloh (Supervisor: PD Dr. Krumbholz)
Yana Parfynova (Supervisor Prof. Dr. Naumann)
Lilei Peng (Supervisor Prof. Dr. Naumann)
Steven Pillen (Supervisor Prof. Dr. Ziemann)
Nikhil Rankan (Supervisor Prof. Dr. Naumann)
Yufei Song (Supervisor Prof. Dr. Ziemann)
Bianca Walter (Supervisor Prof. Dr. Dr. Tabatabai)
Yi Wang (Supervisor PD Dr. Poli)
9Department of Neurology and Stroke
Clinical Studies Precious: PREvention of Complications to Improve OUtcome
in elderly patients with acute Stroke. A randomised, open,
phase III, clinical trial with blinded outcome assessment
Stroke Studies Investigator: PD Dr. Sven Poli
ANNEXA-4: Prospective, open-label study of Andexanet PRESTIGE-AF: PREvention of STroke in Intracerebral hae-
alfa in patients receiving a factor XA-Inhibitor who have morrhaGE survivors with Atrial Fibrillation
acute major bleeding Investigator: PD Dr. Sven Poli
Investigator: PD Dr. Sven Poli
Prodast: Prospective Record Of the use of Dabigatran in
ANNEXA-i: A Phase 4 randomizes clinical trial of Andexanet patients with Acute Stroke or TIA
Alfa (Andexanet Alfa for Injection) in acute intracranial he- Investigator: PD Dr. Sven Poli
morrhage in patients receiving an oral Factor XA Inhibitor
Investigator: PD Dr. Sven Poli PROOF: Penumbral Rescue by Normobaric O=O Administra-
tion in Patients with Ischaemic Stroke and Target Mismatch
APICES: Automatic PredICtion of Edema after Stroke ProFile: A Phase II Proof-of-Concept Trial
(APICES) – Computergestützte automatische Prognose der Investigator: PD Dr. Sven Poli
Entwicklung eines malignen Hirnödems nach Mediainfarkt
Investigator: PD Dr. Sven Poli RASUNOA-Prime: Register für Akute Schlaganfälle Unter
Neuen Oralen Antikoagulantien - Prime
ATTICUS: Apixaban for treatment of embolic stroke of Investigator: PD Dr. Sven Poli
undetermined source
Investigator: PD Dr. Sven Poli REVACEPT (EudraCT-Nr.: 2011-001006-10): An inhibitor of
platelet adhesion in symptomatic carotid stenosis: A phase
AXIOMATIC-SSP: A Global, Phase 2, Randomized, II, multicenter, randomized, dose-finding, double-blind and
Double-Blind, Placebo-Controlled, Dose-Ranging Study of placebo controlled superiority study with parallel groups.
BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention Investigator: PD Dr. Sven Poli
of New Ischemic Stroke or New Covert Brain Infarction in
Patients Receiving Aspirin and Clopidogrel Following Acute RIC-ICH: Register zum Einsatz von Idarucizumab bei
Ischemic Stroke or Transient Ischemic Attack (TIA) Patienten mit intrakranieller Blutung
Investigator: PD Dr. Sven Poli Investigator: PD Dr. Sven Poli
CAPIAS: The carotid plaque imaging in acute stroke (CAPIAS) SANO: Strukturierte ambulante Nachsorge nach
study: protocol and initial baseline data Schlaganfall
Investigator: Prof. Dr. Ulf Ziemann Investigator: PD Dr. Sven Poli
German Stroke Registry SPOCT-NOAC 1: Specific Point-of-Care Testing of
Investigator: PD Dr. Sven Poli Coagulation in Patients Treated with Non-Vitamin K
Antagonist Oral Anticoagulants – Part Ia/b
LYSA: Beobachtungsstudie zur Untersuchung des Investigator: PD Dr. Sven Poli
inhaltlichen Verständnisses eines Aufklärungsgespräches
zur Thrombolyse bei ischämischem Schlaganfall STREAM (ClinicalTrials.gov Identifier: NCT03228251):
Investigator: PD Dr. Sven Poli Simulation-based Training of Rapid Evaluation and
Management for Acute Stroke Trial
PRAISE: Prediction of acute coronary syndrome in acute Investigator: PD Dr. Sven Poli
ischemic stroke
Investigator: Dr. Annerose Mengel TESTdem: Feststellung der Wirksamkeit und Sicherheit der
Transkraniellen Extrakorporalen Stoßwellen-Therapie bei
Patienten mit einer Alzheimer-Demenz
Investigator: PD Dr. Sven Poli
10Annual report 2019
Neuroimmunology studies EmBioPro-MS: Explorative study of emerging blood
biomarkers in progressive multiple sclerosis
AFFINITY (NCT03222973, 215MS202): Investigators: Dr. Ahmed Abdelhak, PD Dr. Markus Krumbholz
Efficacy and Safety of BIIB033 (Opicinumab) as an
Add-on Therapy to Disease-Modifying Therapies (DMTs) ENSEMBLE (EudraCT Nr: 2016-002937-31:
in Relapsing Multiple Sclerosis (MS) This is a prospective, multicenter, open-label, single-arm,
Investigator: PD Dr. Markus Krumbholz phase 3b study which evaluates effectiveness and safety
of ocrelizumab in participants with early stage RRMS. The
CFTY720D2406 PASSAGE (NIS – Phase 4): study will consist of an open-label treatment period of 192
Prospektive, nicht-interventionelle, multinationale Studie weeks and follow-up period of at least 48 weeks
mit Parallel-Kohorten zur Bewertung der Langzeit- Investigator: Prof. Dr. Ulf Ziemann
Sicherheit in Patienten mit MS, deren Behandlung kürzlich
auf tägliche Fingolimod-Gabe umgestellt wurde oder die Ensemble-Plus (NCT03606460): A Study to Evaluate the
mit einer anderen zugelassenen krankheitsmodifizierenden Safety of Administering Ocrelizumab Per a Shorter Infusion
Therapie behandelt werden Protocol in Participants With Primary Progressive Multiple
Investigator: PD Dr. Markus Krumbholz Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
Investigator: Prof. Dr. Ulf Ziemann
CFTY720DDE02 PANGAEA (NIS – Phase 4):
Multizentrische, prospektive, nicht-interventionelle Pangaea 2.0 (CFTY720DDE26): Post-Authorization
Langzeit-Registerstudie zur Beschreibung der Sicherheit Non-interventional GermAn treatment benefit study of
und des Stellenwerts von Gilenya® (fingolimod 0.5 mg) GilEnyA in MS)
in der Behandlung von MS Patienten Investigator: PD Dr. Markus Krumbholz
Investigator: PD Dr. Markus Krumbholz
PROFILE RRMS (ML39348): Evaluation of specific unmet
CLADQoL (MS700568): CLADribine tablets – needs in current clinical practice of multiple sclerosis:
evaluation of Quality of Life characterization of different profiles of relapsing-remitting
Investigator: PD Dr. Markus Kowarik multiple sclerosis patients defined by disease activity and
patient-reported outcomes
CLARION (MS 700568-0002) (NIS – Phase 4): Investigator: PD Dr. Markus Kowarik
Long term, prospective, observational cohort study
evaluating the safety profile in patients with highly REGIMS Register: Ein Immuntherapieregister zur
active relapsing multiple sclerosis (RMS) newly Verbesserung der Arzneimittelsicherheit in der MS-Therapie
started on oral cladribine Investigator: PD Dr. Markus Krumbholz
Investigator: PD Dr. Markus Krumbholz
RETRO (ML39631): A retrospective study investigating
CONFIDENCE (ML39632): Safety and effectiveness best supportive and medical care in clinical practice in
of ocrelizumab under real world conditions: patients with primary progressive multiple sclerosis (PPMS)
a non-interventional post authorization safety study in Germany
in patients diagnosed with relapsing or primary Investigator: PD Dr. Markus Krumbholz
progressive multiple sclerosis
Investigator: PD Dr. Markus Kowarik TRUST (GER-TYS-14-10626): Eine multizentrische,
prospektive, nicht-interventionelle Studie zur Untersuchung
DIFUTURE/ProVal-MS – BMBF-supported, Prospective study der Auswirkung eines integrierten Patientenmanagements,
to validate a multidimensional risk score (DIFUTURE-MSRS) inklusive Biomarkern, Magnetresonanztomographie und
which predicts the 24-month outcome in early Multiple Expertenrat auf den Krankheitsverlauf bei Patienten mit
Sclerosis patients) schubförmiger Multipler Sklerose, die seit mindestens 12
Investigator Tübingen: Prof. Dr. Ulf Ziemann Monaten mit TYSABRI behandelt wurden
Investigator: PD Dr. Markus Krumbholz
11Department of Neurology and Stroke
Clinical Studies Neurooncology Studies
Recruiting trials (open for enrollment)
neuroimmunology Studies BMS-CA209-548 (NCT02667587): Study of Temozolomide
Plus Radiation Therapy With Nivolumab or Placebo, for
WA 21493 OLE (EudraCT-Nr. 2007-006338-32): Newly Diagnosed Patients With Glioblastoma (GBM,
A phase II, multicenter, randomized, placebo and Avonex a Malignant Brain Cancer) (CheckMate548)
controlled dose finding study to evaluate the efficacy and Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai
safety of ocrelizumab in patients with relapsing-remitting Sponsor: BMS
multiple sclerosis
Investigator: Prof. Dr. Ulf Ziemann AbbVie M13-813 (NCT02573324): A study of ABT-414 in
subjects with newly diagnosed Glioblastoma (GBM) with
WA21092 OPERA (EudraCT-Nr. 2010-020337-99): Epidermal Growth Factor Receptor (EGFR) amplification
A randomized, double-blind, double-dummy, parallel-group (Intellance 1)
study to evaluate the efficacy and safety of ocrelizumab in Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai
comparison to interferon beta-1a (Rebif®) in patients with Sponsor: RTOG and AbbVie
relapsing multiple sclerosis
Investigator: Prof. Dr. Ulf Ziemann iMRI/5-ALA: A parallel group phase II trial to investigate
maximum extent of resection based on iMRI versus 5-ALA
WA25046 ORATORIO (EudraCT-Nr.2010-020338-25): Lead Principal Investigators: PD Dr. Constantin Roder,
A phase III, multicenter, randomized, parallel-group, Prof. Dr. Marcos Tatagiba
double-blinded, placebo-controlled study to evaluate the Sponsor: University Hospital Tübingen
efficacy and safety of ocrelizumab in adults with primary
progressive multiple sclerosis. NOA-10 (NCT01252459): Amino-acid PET versus MRI-
Investigator: Prof. Dr. Ulf Ziemann guided re-irradiation in patients with recurrent Glioblasto-
ma Multiforme (GLIAA)
Investigator in Tübingen: Prof. Dr. Daniel Zips
Sponsor: University Hospital Freiburg
NOA-16 (NCT02454634): Phase I trial of IDH1-peptide
vaccine in IDH1R132H-mutated grade III-IV gliomas
Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai
Sponsor: University Hospital Heidelberg
Bayer 18239 (NCT02746081): Phase I study of BAY1436032
in Isocitrate Dehydrogenase-1 (IDH1)-mutant advanced
solid tumors
Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai
Sponsor: Bayer
EORTC 1320: Phase II trial in atypical and anaplastic
meningioma
Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai
Sponsor: EORTC
12Annual report 2019
Neurooncology Studies GAPVAC-101: A phase I study using an innovative
trials in treatment and follow-up phase individualized peptide-vaccination-based
(enrollment Closed) immunotherapy in newly diagnosed glioblastoma
(www.gapvac.eu)
NOA12: Phase I/II trial exploring the combination of the Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai
compound BIBF120 with re-irradiation versus re-irradiation Sponsor: Immatics GmbH, Tübingen
alone in progressive glioblastoma.
Investigator in Tübingen: Prof. Dr. Daniel Zips CeTeG (NCT01149109): Efficacy and safety study of
Sponsor: University Hospital Heidelberg Lomustine/Temozolomide combination therapy versus
standard therapy for glioblastoma patients
BMS CA 209-498 (NCT02617589): Phase III trial of Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai
Nivolumab Compared to Temozolomide, Given With Sponsor: University Hospital Bonn
Radiation Therapy, for Newly-diagnosed Patients With
Unmethylated Glioblastoma (GBM, a Malignant Brain CATNON Intergroup Trial (EORTC 26053): Phase III
Cancer) (CheckMate 498) trial on concurrent and adjuvant temozolomide
Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai chemotherapy in non-1p/19q deleted anaplastic
Sponsor: BMS glioma
Investigator: Prof. Dr. Dr. Ghazaleh Tabatabai
EORTC1410/AbbVie M14-483 (NCT02343406): ABT-414 Sponsor: EORTC
Alone or ABT-414 Plus Temozolomide vs. Lomustine or
Temozolomide for recurrent glioblastoma (INTELLANCE 2) EORTC 26101 (NCT01290939): Bevacizumab and
Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai Lomustine for Recurrent GBM
Sponsor: EORTC Investigator: Prof. Dr. Dr. Ghazaleh Tabatabai
Sponsor: EORTC
CINC280X2204 (NCT01870726): Safety and efficacy
of INC280 and Buparlisib (BKM120) in patients with
recurrent gliobastoma
Investigator in Tübingen: Prof. Dr. Dr. Ghazaleh Tabatabai
Sponsor: Novartis
13Department of Neurology and Stroke
Third-Party Funding The role of MTUS/ATIP1 in glioblastoma progression and
invasion
Project leader: Prof. Dr. Ulrike Naumann
Ongoing Grants Funding institution: DAAD
Explorative study of emerging blood biomarkers in Assessment of YB-1 Dependent Oncolytic Adenovirus-Based
progressive multiple sclerosis (EmBioProMS) Glioma-Virotherapy on Cellular Immune Responses
Project leader: Dr. Ahmed Abdelhak (NA 770/4-1)
Funding Institution: Deutsche Multiple Sklerose Gesellschaft Project leader: Prof. Dr. Ulrike Naumann
(DMSG) Funding institution: German Research Foundation (DFG)
The sensorimotor μ-rhythm as cholinergically controlled Automatic PredICtion of Edema after Stroke (APICES)
pulsed inhibition Project leader: PD Dr. Sven Poli
Project leader: Dr. Til Ole Bergmann Funding institution: Innovationsausschuss beim
Funding institution: German Research Foundation (DFG) Gemeinsamen Bundesausschuss (GBA)
The role of B cells in patients with gliomas: Specific Point-of-Care Testing of Coagulation In Patients
B cell associated immuno-surveillance in the CNS? Treated with Edoxaban (SPOCT-Edoxaban)
Project leader: PD Dr. Markus Kowarik Project leader: PD Dr. Sven Poli
Funding Institution: Medical Faculty University Tübingen, Funding institution: Daiichi Sankyo
fortüne Program
Penumbral Rescue by normobaric O=O Administration in
Immunoglobulin (Ig) repertoire analysis in multiple patients with ischemic Stroke and target mismatch profile:
sclerosis patients treated with cladribine (Mavenclad) A phase II Proof-of-Concept Trial
- A combined Ig transcriptome and proteome approach - Project leader: PD Dr. Sven Poli
Project leader: PD Dr. Markus Kowarik Funding institution: European Commission
Funding Institution: Merck GmbH
Immunoglobuline repertoire analysis in multiple sclerosis
Immunoglobulin (Ig) repertoire analysis in multiple Project leader: Dr. Christoph Ruschil
sclerosis patients treated with teriflunomid (Aubagio) Funding Institution: Medical Faculty University Tübingen,
- A combined Ig transcriptome and proteome approach - PATE Program
Project leader: PD Dr. Markus Kowarik
Funding Institution: Genzyme Multipeptide vaccination with a new immunomodulatory
agent XS15 in newly diagnosed glioblastoma:
Beeinflussung des klinischen Verlaufes von neurologischen a first in man phase 1 trial
Intensivpatienten durch autoregulationsbasiertes zerebrales Project leader: Prof. Dr. Dr. Ghazaleh Tabatabai,
Perfusionsmanagement Prof. Dr. Hans-Georg Rammensee
Project leader: Dr. Annerose Mengel Funding institution: Medical Faculty Tübingen
Funding Institution: Medical Faculty University Tübingen,
TüFF Program Individualizing the treatment of CNS Metastases
Project leader: Prof. Dr. Dr. Ghazaleh Tabatabai
Cardiac Autonomic Function for Risk Prediction in Funding institution: Medical Faculty Tübingen
Cryptogenic Stroke (CRYPTIC-Study)
Project leaders: Prof. Dr. Christine Meyer-Zürn, EKFS-Forschungskolleg „Therapieresistenz solider Tumore”
PD Dr. Sven Poli, Prof. Dr. Jennifer Diedler Project leader: Prof. Dr. Dr. Ghazaleh Tabatabai
Funding institution: Medtronic Funding institution: Else Kröner Fresenius-Stiftung
14Annual report 2019
Strengthening the SMA-M1 connection of human motor EXIST Forschungstransfer: NEUROSYNC
cortex by a novel non-invasive brain stimulation protocol Project leader: Dr. Christoph Zrenner
to enhance motor performance and learning Funding institution: Federal Ministry of Education and
(DFG ZI 542/7-1) Research (BMBF)
Project leader: Prof. Dr. Ulf Ziemann
Funding institution: German Research Foundation (DFG) Induction of brain plasticity with closed-loop EEG-triggered
transcranial magnetic stimulation
Implantable, bidirectional brain-computer-interface for Project leader: Dr. Christoph Zrenner
restoration of motor functions (MOTOR-BIC) Funding institution: Medical Faculty University Tübingen,
Leaders for Tübingen Project: Prof. Dr. Niels Birbaumer, Clinician Scientist Program
Prof. Dr. Ulf Ziemann
Funding institution: Federal Ministry of Education and
Research (BMBF) New Grants
Apixaban for treatment of embolic stroke of undetermined Pre-stimulus µ-rhythm phase differentially effects low-
source (ATTICUS randomized trial) frequency repetitive TMS-induced corticospinal excitability
Project leaders: Prof. Dr. Tobias Geisler, Prof. Dr. Ulf Ziemann Project leader: Dr. David Baur
Funding institution: Bristol-Myers Squibbs Funding institution: Medical Faculty University Tübingen,
Junior Clinician Scientist Program
An exploratory study assessing TMS plasticity deficits in
patients with AD and aMCI in comparison to healthy Der Einfluss des EMT-Proteins SLUG auf die Integrität der
controls Blut-Hirn-Schranke im GBM - in vitro Analysen
Project leaders: Prof. Dr. Ulf Ziemann, Prof. Dr. Daniela Berg, Project leader: Prof. Dr. Ulrike Naumann
Prof. Dr. Christoph Laske Funding institution: IZKF Promotionskolleg
Funding institution: Janssen Pharmaceuticals NV
Untersuchungen zum Einfluss von gliom-sezerniertem
Transcranial magnetic stimulation; Electroencephalo- TGF-ß auf die Struktur Gliom-assoziierter Gefäße:
graphy; TMS-EEG; human cortex; excitability; neuro- Erstellung von murinen TGF-ßKO Gliomzellen mittels
pharmacology; glutamatergic system; GABAergic system; CRISPR/Cas und Charakterisierung der Zelllinien
voltage-gated ion channels; anticonvulsants (ZI 542/9-1) Project leader: Prof. Dr. Ulrike Naumann
Project leader: Prof. Dr. Ulf Ziemann Funding institution: IZKF Promotionskolleg
Funding institution: German Research Foundation (DFG)
Intranasal delivery of cellular “Trojan Horse” cells
DIFUTURE/ProVal-MS – Prospective study to validate a multi- loaded with oncolytic adenovirus to treat invasive
dimensional risk score (DIFUTURE-MSRS) which predicts the recurrent glioblastoma
24-month outcome in early Multiple Sclerosis patients) Project leader: Prof. Dr. Ulrike Naumann
Clinical project leader Tübingen: Prof. Dr. Ulf Ziemann Funding institution: German Cancer Foundation
Funding institution: Federal Ministry of Education and
Research (BMBF) Pericyte function in the glioblastoma vascule
Project leader: Prof. Dr. Ulrike Naumann
Connecting to the Networks of the Human Brain Funding institution: Chinese Sholarship Council
(ConnectToBrain)
Project leaders: Prof. Dr. Ulf Ziemann, Reconnecting the ageing brain to enhance plasticity
Prof. Dr. Risto Ilmoniemi (Aalto University, Finland), and motor learning
Prof. Dr. Gian-Luca Romani (Universita degli studi Gabriele Project leaders: Prof. Dr. John Semmler (Adelaide University),
d’Annunzio di Chieti-Pescara, Italy) Co-PI: Prof. Dr. Ulf Ziemann
Funding Institution: European Research Council (ERC) Funding institution: Australian Research Council (ARC)
Synergy Program
15Department of Neurology and Stroke
Awards Medical Theses
(Completed in 2019)
Prof. Dr. Ulf Ziemann
Listing “Top Physicians 2019” (Guter Rat) Julia Kiraly
The role of GABAAergic neurotransmission in the human
Prof. Dr. Dr. Ghazaleh Tabatabai brain probed by paired-pulse TMS-EEG
Listing “Top physician 2019” (Brain Tumor Treatment) Supervisor: Prof. Dr. Ulf Ziemann
PhD Theses
(Completed in 2019)
Sonja Schötterl
Functional and therapeutic effects of viscumins in the
treatment of experimental glioblastoma
Supervisor: Prof. Dr. Ulrike Naumann
Master Theses
(Completed in 2019)
Maya Velardi
Neuere Ansätze in der Aphasietherapie
Supervisor: Prof. Dr. Ingo Hertrich
16Annual report 2019
Bachelor Theses Guest Researchers
(Completed in 2019)
Dr. Jaakko Nieminen, Aalto University, Finland
Fee Arnold (Funded by the National Academy of Science, Finland)
It’s all about irony Host: Prof. Dr. Ulf Ziemann
Supervisor: Prof. Dr. Ingo Hertrich
Jule Kalessa
Das Tourette Syndrom - Kann die Krankheit zu einer
besseren Verarbeitung linguistischer Prozesse führen?
Supervisor: Prof. Dr. Ingo Hertrich
Lea Glauner
Sprachverhalten bei Menschen mit Depression –
prosodische und linguistische Merkmale
Supervisor: Prof. Dr. Ingo Hertrich
Amelie Winter
Is a naive discriminative learning model an appropriate
candidate for replacing cloze tasks?
Supervisor: Prof. Dr. Ingo Hertrich
Patricia Zwicker
Bilingual aphasia - does bilingualism have a beneficial
effect on recovery from (post-stroke) aphasia?
Supervisor: Prof. Dr. Ingo Hertrich
17Department
of Neurology
and
Epileptology
Clinical and Scientific Staff scIentIsts/resIdents
Murtadha Alshabaan
HeAd of tHe depArtment Dr. Christian Boßelmann
Dr. Ahmed Eltokhi
Prof. Dr. Holger Lerche Dr. Samira Hamzehian
Dr. Ulrike Hedrich-Klimosch
Dr. Yiwen Li Hegner
group leAders/AttendIng pHysIcIAns Dr. Dr. Randolph Helfrich
Dr. Josua Kegele
Prof. Dr. Niels Focke (partially affiliated) Dr. Silke Klamer
Prof. Dr. Tobias Freilinger (partially affiliated) Dr. Henner Koch
Prof. Dr. Alexander Grimm Dr. Stephan Lauxmann
Dr. Pascal Martin (since March 2019) Dr. Yuanyuan Liu
Dr. Melanie Schreiber (since April 2019) Dr. Justus Marquetand
PD Dr. Sigrid Schuh-Hofer (partially affiliated) Dr. Joohyun Park
Prof. Dr. Yvonne Weber Dr. Lorenzo Roncoroni
(until September 2019, then partially affiliated) Filip Rosa
Dr. Stefan Wolking (until March 2019) Dr. Victoria Schubert
Dr. Laura Schurr
Dr. Niklas Schwarz
Jan-Hendrik Stahl
Sabine Thewes
Dr. Nathalie Winter
Dr. Sophia Willikens
Dr. Thomas Wuttke
18Annual report 2019
Technical staff/ MD/phd Students Internships
Administration
Jacqueline Bahr Marei Brose
Yvonne Brändle Erva Bayraktar Supervisor: Dr. Stephan Lauxmann
Ana Fulgencio-Maisch Carolin Fischer
Merle Harrer Moritz Hanke Julia Koppelmann
Christian Hengsbach Haosi Huang Supervisor: Betül Uysal
Sabrina Kreiser Mahmoud Koko Musa
Heidrun Löffler Raviteja Kotikalapudi Kalaivani Manibarathi
Sarah Rau Johanna Krüger Supervisor: Dr. Ulrike Hedrich
Elisabeth Schriewer Nicole Kusch
Robert Lauerer Emilio Pardo
Nikolas Layer Supervisors: Johanna Krüger,
Hang Lyu Nikolas Layer, Dr. Henner Koch
Anjela Meyer
Daniela Miely Lorena Savini
Harshad Pannikkaveettil Ashraf Supervisor: Dr. Stephan Lauxmann
Simone Seiffert
Pauline Scheuber Zeynep Yentur
Hannah Schwarz Supervisor: Betül Uysal,
Lukas Sonnenberg Dr. Ulrike Hedrich
Christina Stier
Pu Yan
Nan Zhan
19Department of Neurology and Epileptology
Clinical Studies BIA-2093-213 - prevention of epilepsy in stroke patients at
high risk of developing unprovoked seizures:
anti-epileptogenic effects of eslicarbazepine acetate
LIBERTY / CAMG334A2301 – a 12-week double-blind, Investigator: Prof. Dr. Holger Lerche
randomized, multicenter study comparing the efficacy
and safety of once monthly subcutaneous 140 mg TUNAP – Studie zur Evaluierung der Rolle des
AMG 334 against placebo in adult episodic migraine Nervenultraschalls bei Nerventraumata
patients who have failed 2-4 prophylactic treatments Investigators: Prof. Dr. Alexander Grimm, Dr. Nathalie Winter,
Investigators: Prof. Dr. Tobias Freilinger, Dr. Martin Schuhmann (Neurochirurgie), Prof. Dr. Adrien
Prof. Dr. Holger Lerche Daigeler (BGU Tübingen), Jan-Hendrik Stahl, Dr Josua Kegele,
Dr. Sophia Willlikens, Julia Wittlinger
HeMiLa – Prophylactic treatment of hemiplegic migraine
with lamotrigine UPSS – Pattern Analysis bei Neuropathien
Investigators: Prof. Dr. Tobias Freilinger, Investigators: Prof. Dr. Alexander Grimm, Dr. Nathalie Winter,
Prof. Dr. Holger Lerche Jan-Hendrik Stahl, Dr Josua Kegele, Dr. Sophia Willlikens,
Julia Wittlinger, Debora Vittore-Welliong
VOTE / EP0076 – Patient preferences in epilepsy mono-
therapy – a non-intervnetional study of lacosamide and MUSS – Muskelsummenscore zur Evaluierung der
other antiepileptic drugs in the treatment of partial-onset Muskelfibrose bei Neuropathien
seizures, including a discrete choice experiment Investigators: Prof. Dr. Alexander Grimm, Dr. Nathalie Winter
Investigator: Prof. Dr. Holger Lerche
Follow-Up PNP - Ultrasound, electrophysiology and clinical
ARISE / EP0091 – A randomized, double-blind, placebo- follow-up study of patients with Immune-mediated
controlled, dose finding study to evaluate the efficacy and neuropathies (in cooperation with CSL Behring)
safety of padsevonil as adjunctive treatment of focal-onset Investigators: Prof. Dr. Alexander Grimm, Dr. Nathalie Winter,
seizures in adult subjects with drug-resistant epilepsy Jan-Hendrik Stahl, Dr Josua Kegele, Dr. Sophia Willlikens,
Investigators: Prof. Dr. Yvonne Weber, Prof. Dr. Holger Lerche Julia Wittlinger
EE / AKF357-0-0 – Pathophysiologie basierte Therapie von Ultrasound in inherited neuropathies and TTR-Amyloidosis
früh beginnenden epileptischen Enzephalopathien - ultrasound aspects of hereditary neuropathies
Investigators: Prof. Dr. Yvonne Weber, Dr. Michael Alberg Investigators: Prof. Dr. Alexander Grimm, Dr. Nathalie Winter,
Jan-Hendrik Stahl, Dr Josua Kegele, Dr. Sophia Willlikens,
EP0093 - an open-label, multicenter, extension study to Julia Wittlinger, Debora Vittore-Welliong
evaluate the safety and efficacy of padsevonil as adjunctive
treatment of focal-onset seizures in adult subjects with Tram2 – Screening for TTR-Amyloiosis in patients with ax-
drug-resistant epilepsy onal neuropathy (in cooperation with Centogene Rostock)
Investigators: Prof. Dr. Yvonne Weber, Prof. Dr. Holger Lerche Investigators: Prof. Dr. Alexander Grimm, Dr. Nathalie Winter,
Jan-Hendrik Stahl, Dr Josua Kegele, Dr. Sophia Willlikens,
HerMes / CAMG334ADE01 - a randomized, double-blind, Julia Wittlinger, Debora Vittore-Welliong
multicenter head-to-head study of erenumab against
topiramate - migraine study to assess tolerability and I-Guide – Follow-Up Study of CIDP and MMN patients with
efficacy in a patient-centered setting treatment of ivIG (in cooperation with Grifols)
Investigator: Prof. Dr. Holger Lerche Investigators: Prof. Dr. Alexander Grimm, Dr. Nathalie Winter,
Jan-Hendrik Stahl, Dr Josua Kegele, Dr. Sophia Willlikens,
Spectre / CAMG334ADE02 - Characerisation of prescription Julia Wittlinger
patterns In episodic and chronic migraine patients starting
treatment in a reallife setting with erenumab in Germany
Investigator: Prof. Dr. Holger Lerche
20Annual report 2019
Third-Party Funding Trimodale Bildgebung humaner Hirnnetzwerke mittels
simultaner PET/MR/EEG
Project leader: Prof. Dr. Niels Focke (together with
ongoing Grants Prof. Dr. Christian la Fougere und Prof. Dr. Bernd Pichler)
Funding Institution: German Research Foundation (DFG)
Pathophysiology of familial hemiplegic migraine:
Examination of a newly developed transgenic SCNC1A Effect of Eslicarbazepine on genetic gain-of-function
mouse model mutations in voltage-gated Na+ channels causing
Project leader: PD Dr. Tobias Freilinger epilepsies in young children
Funding institution: German Research Foundation (DFG) Project leader: Prof. Dr. Holger Lerche, Dr. Stephan Lauxmann
Funding Institution: Bial
Pathophysiology of non-classical epileptic
encephalopathies (EE) Neurological Clinical Problem Solving (Neuro-CliPS)
Project leader: Prof. Dr. Yvonne Weber Tübingen
Funding institution: German Research Foundation (DFG) Project leader: Prof. Dr. Tobias Freilinger
Funding institution: University of Tuebingen, PROFIL
Pathophysiology-triggered therapy of epileptic programme
encephalopathies
Project leader: Prof. Dr. Yvonne Weber Guest Physician Stipend
Funding institution: AKF (Angewandte Klinische Forschung), Project participant: Murtadha Alshabaan
University of Tübingen Funding institution: Saudi-Arabia
Prophylactic treatment of hemiplegic migraine with DFG-Research Unit FOR2715
lamotrigine – a pilot study ‘Epileptogenesis of genetic epilepsies’
Project leader: PD Dr. Tobias Freilinger Speaker: Prof. Dr. Holger Lerche
Funding institutions: Centre for Rare Diseases (ZSE) Funding institution: German Research Foundation (DFG),
and AKF, University of Tübingen additional funding by the FNR (Luxembourg):
including the following five grants:
Exploring the function of the central control of breathing
in mice with sodium-channel mutations causing epilepsy, P1: Genetic mechanisms of epileptic encephalopathies
implications for sudden unexpected death in patients with Project leader: Prof. Dr. Yvonne Weber
epilepsy (SUDEP) (with Prof. Dr. Ingo Helbig from Kiel University)
Project leader: Dr. Henner Koch
Funding institution: German Research Foundation (DFG) P2: Rare genetic factors in epileptogenesis
Project leader: Prof. Dr. Holger Lerche
DAAD PhD Stipendium (with Prof. Dr. Michael Nothnagel from Cologne University
Project participant: Mahmoud Koko and Dr. Roland Krause from Luxembourg University)
Funding institution: DAAD
P5: Brain region-specific epileptogenesis in a conditional
Network-Imaging in genetic epilepsy mouse model
Project leader: Prof. Dr. Niels Focke Project leaders: Prof. Dr. Holger Lerche, Dr. Henner Koch,
Funding Institution: German Research Foundation (DFG) Dr. Thomas Wuttke
Non-invasive vagal nerve stimulation (nVNS) for acute P6: Mechanisms of epileptogenesis in KCNA2-/SCN2A-
treatment of prolonged aura in hemiplegic migraine – mediated epilepsies
an open-label, single-arm, multiple attack pilot trial Project leader: Dr. Ulrike Hedrich
Project leader: Prof. Dr. Tobias Freilinger (with Prof. Dr. Olga Garaschuk from Tübingen University)
Funding institution: Centre for Rare Diseases,
University of Tübingen Z3: Central Management
Project leader: Prof. Dr. Holger Lerche
21Department of Neurology and Epileptology
Third-Party Funding NEW GRANTS
TreatION - New therapies for neurologic ion channel and
ongoing GRANTS transporter disorders
Speaker: Prof. Dr. Holger Lerche
Spreading of pathological activity in critical brainstem Funding institution: Federal Ministry of Education and
centers and activation measured in vivo in a Dravet mouse Research (BMBF)
Model
Project leader: Dr. Henner Koch TP1: Coordination, Mol.-Therap. Board, an d existing rare
Funding institution: Finding a Cure for Epilepsy and Seizures disease initiatives
(FACES) Project leader: Prof. Dr. Holger Lerche
(with Dr. Holm Graessner from Centre of Rare Diseases -
Personalisierte Therapieoptionen für Patienten mit University of Tübingen)
KCNA2-assoziierten epileptischen Enzephalopathien
Project leader: Dr. Ulrike Hedrich TP2: Data integration and in silico precision medicine for
Funding institution: Eva Luise und Horst Köhler Stiftung neurological ion channel and transporter disorders
Project leader: Prof. Dr. Yvonne Weber
Entwicklung eines Anfallsdetektors (with Dr. Sarah von Spiczak from University Medical Center
Project leader: Prof. Dr. Yvonne Weber Schleswig-Holstein - Campus Kiel and Roland Krause from
Funding institutions: Federal Ministry of Education and Luxembourg Centre for Systems Biomedicine Univ. of
Research/Life Science Incubator Bonn (BMBF/LSI Bonn) Luxembourg)
SNAREopathies - Mechanismen neuropsychiatrischer, TP7: Multimodal analysis of novel mouse models
genetischer Erkrankungen des SNARE-Komplexes: associated with glutamate transporter dysfunction
Hin zu therapeutischen Maßnahmen Project leader: Dr. Ulrike Hedrich
TP Tübingen: Funktionelle Analyse anhand von transgenen (with Prof. Dr. Nikolaus Plesnila from LMU Munich)
Mausmodellen, die Träger des krankheitsverursachenden
Gens sind TP8: Pathophysiology and therapy in human neuronal
Project leader: Prof. Dr. Holger Lerche models of KCNA2 channelopathies
Funding institution: Federal Ministry of Education and Project leader: Prof. Dr. Holger Lerche, Dr. Henner Koch,
Research (BMBF) Dr. Niklas Schwarz
Doktorandenstipendium – Projekt: computer-basierte Single-cell transcriptome sequencing to investigate
Modellrechnungen zur Änderung des Verhaltens von mechanisms of epileptogenesis in genetic mouse models
Nervenzellen bei genetischen Epilepsien and human brain biopsy tissue
Project leader: Prof. Dr. Holger Lerche Project leader: Dr. Ulrike Hedrich, Dr. Henner Koch
Funding institution: Stiftung no epilep (with Prof. Dr. Albert Becker from University of Bonn and
Prof. Dr. Dirk Isbrandt University of Cologne)
UNAP-Projekt bei Nervenverletzung Funding institution: German Research Foundation (DFG)
Project leader: Prof. Dr. Alexander Grimm, Dr. Nathalie Winter
Funding institution: Deutsche Gesellschaft für Ultraschall Establishment of a human electrophysiological model
in der Medizin (DEGUM) to quantify the CGRP-related axon reflex of trigeminal
afferents and its evaluation as a clinical tool to assess
and predict treatment effects of migraine prophylaxis
Project leader: Dr. Victoria Schubert
Funding institution: Medical Faculty,
University of Tübingen
22Annual report 2019
Genetics and pharmakogenetics of epilepsies Awards
Project leader: Dr. Stefan Wolking
Funding institution: University of Tübingen Prof. Dr. Alexander Grimm
(Clinician Scientist) 2nd Felix-Jerusalem Award of the German Society for
Muscle Diseases (DGM)
Role of common and rare genetic factors In the etiology of
genetic epilepsies and pharmacoresponse Victoria Schubert, Sigrid Schuh-Hofer
Project leader: Dr. Stefan Wolking Soyka Förderpreis für Schmerzforschung
Funding institution: German Research Foundation (DFG)
Investigation of novel treatment strategies for idiopathic
epilepsy: from genetic modulation of neuronal network PhD Theses
activity in vivo to transplantation of MGE-derived (Completed in 2019)
interneurons
Project leader: Dr. Thomas Wuttke Ravitejah Kotikalapudi
Funding institution: Medical Faculty, Voxel based morphometry of the human brain in epilepsy
University of Tübingen Supervisor: Prof. Dr. Niels Focke
Somatotopia and fascikelarchitektur im gesunden und
neuropathischen Nerv
Project leader: Dr. Natalie Winter MD Theses
Funding Institution: University of Tübingen (Completed in 2019)
(Clinician Scientist Program)
Josua Kegele
Genetische Ursachen des Nodding-Syndroms und
familiärer Epilepsien in Subsahara-Afrika
Conferences & Workshops Supervisor: Prof. Dr. Holger Lerche
DGN Facharztrepetitorium Neurologie 2019 Nicole Kusch
Tübingen, 21 - 22 February 2019 Beeinflussung kardiorespiratorischer Parameter bei
Scientific coordinators: Prof. Dr. Holger Lerche, Patienten mit Epilepsie
Prof. Dr. Tobias Freilinger, Dr. Stefan Wolking Supervisor: Prof. Dr. Yvonne Weber
Ultraschall Seminar
Tübingen, 6 April 2019
Scientific coordinator: Prof. Dr. Alexander Grimm Bachelor Theses
(Completed in 2019)
Tübinger Therapiefortbildung Neurologie
Tübingen, 20 July 2019 Marietheres Evers
Scientific coordinators: Prof. Dr. Holger Lerche, Functional Characterization of mutations in the
Pascal Martin potassium channel gene KCND3 causing a spectrum of
neuropathological symptoms
Young Neurologists Summer School 2019 Supervisors: Dr. Ulrike Hedrich, Mahmoud Koko
Tübingen,29 July - 2 August 2019
Scientific coordinators: Prof. Dr. Holger Lerche, Eva Kunzelmann
Dr. Christian Boßelmann, Dr. Sophia Willikens Measuring of Synchronic Rhythmic Activity in Wildtype
and Pathologically Altered Brain Slices and the Response
to the Sodium Channel Blocker Eslicarbazepine
Supervisor: Dr. Stephan Lauxman
23Department of Neurodegenerative Diseases
Department
of Neuro-
degenerative
Diseases
Clinical and Scientific Staff scIentIsts/resIdents/pHd students
Sara Becker
HeAd of tHe depArtment Dr. Friedemann Bender
Maria Sophie Breu
Prof. Dr. Thomas Gasser Idil Cebi
Silvia De Cicco
Mohamad Dehestani
deputy HeAd of tHe depArtment Marita Eckert
Zofia Fleszer
Prof. Dr. Ludger Schöls Dr. Natalja Funk
Dr. Sven Geisler
Dr. Shabab Hannan
group leAders/AttendIng pHysIcIAns Dr. Friederike Hans
Dr. Stefan Hauser ( jointly with DZNE)
Dr. Kathrin Brockmann Dr. Stefanie Hayer
Jun.-Prof. Dr. Dr. Michela Deleidi ( jointly with DZNE) Dr. Holger Hengel
Dr. Julia Fitzgerald Anna Hofmann
PD Dr. Christian Johannes Gloeckner ( jointly with DZNE) Philip Höflinger
Prof. Dr. Philipp Kahle Mohammad Hormozi
PD Dr. Inga Liepelt-Scarfone Dr. Dina Ivanyuk
PD Dr. Rebecca Schüle Dr. Christoph Kessler
Prof. Dr. Matthis Synofzik Felix Knab
Prof. Dr. Daniel Weiß Milena Korneck
Stefanie Krüger
Dr. Stefanie Lerche
AffIlIAted eXternAl group leAders Hui Liu
Dr. Ebba Lohmann
Prof. Dr. Daniela Berg Dr. Gerrit Machetanz
Prof. Dr. Rejko Krüger Dr. David Mengel
Jorge Garcia Morato
Maike Nagel
Dr. Vasiliki Panagiotakopoulou
24Annual report 2019
Dr. Tim Rattay Benjamin Riebenbauer Malte Kampmeyer
Dr. Benjamin Roeben Elisabeth von Schalkwyk (until Irenee Kanyiki
Dr. Anna Schöllmann (until 06/2019) 01/2019) Kristina Kaufhold
Dr. Marlieke Scholten Yvonne Schelling ( jointly with DZNE) Sarah Klatt
Claudia Schulte Susanne Stimmler Teresa Klos
Stefanie Schuster Elke Stransky Annika Koch
Lisa Schwarz Dr. Anna-Katharina von Thaler Leonie Köhler
Patricia Sulzer Doris Wieder Sebastian Kormeier
Ulrike Sünkel Ina Wolfstädter Sandra Lachenmaier
Anna Lechado Terradas Cong Yu Lena Löffler
Catherine Thömmes Maria Zarani Katrin Maier
Dr. Dr. Andreas Traschütz Nicole Zweig ( jointly with DZNE) Julian Meinhardt
Ulrike Ulmer Julia Maren Ott
Dr. Sarah Wiethoff Sascha Otterbein
Dr. Carlo Wilke Medical Doctoral Sylvia Pflederer
Dr. Isabel Wurster Students Kathrin Prahl
Dr. Lena Zeltner David Rieger
Dr. Milan Zimmermann Merit Bade Lea Rietschel
Kristina Bettecken Pavel Saraykin
Aline Beyle Jennifer Sartor
Technical staff/ Andreas Boldt David Scheibner
Administration Vera Borowski Anne-Sophie Schmitz
Jan-Hinrich Busch Patricia Schöpfer
Marcel Armbruster Gabriela Carvajal Hans Justus Siegrist
Klaus Beyreuther Monique Dehnert Johannes Sprengel
Christian Deuschle Steffen Dengler Lena Stetz
Katrin Dillmann Lisanne Dormann Stefanie Straub
Christian Erhardt Karl Friedrich Ermisch Stefan Streich
Dr. Jutta Eymann Zofia Fleszar Inga Caroline Thielker
Dr. Bettina Faust Amina Flinsbach Marlene Topka
Ann-Kathrin Hauser Florian Funer Maximilian Völker
Manuela Hauser Sarah Gascon-Busquet Melanie Wayand
Tanja Heger Ina Gehweiler Sofie Weiss
Heiderose Heiss Julia Göddel-Sand Katarzyna Wojcik
Ella Hilt Judith Greiner Nicolas Zang
Susanna Hoffmann Katharina Greulich Laura Zaunbrecher
Marina Karakhanyan Kilian Gunkel
Mirjam Knöll Alexandra Gutfreund
Melanie Kraft Elena Hager
Alejandra Leyva Jochen Hallwachs
Isolde Marterer Linda Härtner
Petra Mech Melanie Heilbronn
Katja Michaelis Kim-Susann Hennefarth
Doreen Müller Hanna Hentrich
Susanne Nussbaum Dominik Hermle
Dr. Angelika Oehmig Markus Hobert
Miriam Peleman Max Hollweck
Gabriela Ragusa Daniel Holz
Selina Reich Svenja Hucker
Jennifer Reichbauer Sofie Kämereit
25Department of Neurodegenerative Diseases
Clinical and Scientific Staff Clinical Studies
Master & Bachelor PPMI – The Parkinson’s Progression Markers Initiative
Students (please see: http://www.ppmi-info.org/)
Multicenter longitudinaI observational study in PD
Orchid Ammar Investigators: Dr. Kathrin Brockmann
Carina Arnold
Marissa Bentele P-PPMI (please see also: Fox-Trial-Finder): Prodromal
Olga Böttinger Parkinson’s Progression Markers Initiative: Multicenter
Sofie Englisch longitudinaI observational study in individuals at risk for PD
Marie Gauder Investigators: Dr. Kathrin Brockmann
Elena Heuten
Huong Giang Hoang PPMI Genetic Cohort: Multicenter longitudinaI
Benedikt Hölbling observational study in genetic PD
Milena Korneck Investigators: Dr. Kathrin Brockmann
Kim Krieg
Hannah Lönnecker Roche Pasadena Studie BP39529: a randomized,
Kalaivani Manibarathi double-blind, placebo-controlled, 52-week phase II study
Max Mattheuer to evaluate the efficacy of intravenous RO7046015
Madeline Nagel (PRX002) in participants with early Parkinson’s Disease
Lara Sophie Rieder with a 52-week blinded extension Pasadena
Srinethe Saravanan Investigators: Dr. Kathrin Brockmann, PD Dr. Inga Liepelt-
David Skrabak Scarfone, Prof. Dr. Thomas Gasser
Jule Truberg
Deborah Wolf Influence of Inflammatory Profiles on PD Phenotype and
Progression
Investigator: Dr. Kathrin Brockmann
Bundesfreiwilligen-
dienstleisterinnen Kognitive Stimulation bei Patienten mit Parkinson-
Demenz: Wirksamkeit, Prädiktoren des Trainingserfolgs
Lea Hetzinger und gesundheitsökonomische Evaluation
Meike Keller (until 08/2019) Investigator: PD Dr. Inga Liepelt-Scarfone
Annika Weger
Marie Wiesemann (until 08/2019) Cognitive-driven ADL impairment as a predictor for
Parkinson’s disease Dementia (PDD)
Investigator: PD Dr. Inga Liepelt-Scarfone
ABC-PD: a monocenter longitudinal study on the predictive
value of CSF abeta-pathology for PD dementia.
Investigators: PD Dr. Inga Liepelt-Scarfone,
Prof. Dr. Daniela Berg, Prof. Dr. Walter Maetzler
26Annual report 2019
TREND-Studie (Tübinger evaluation of Risk factors for Early AGN191622: BOTOX prophylaxis in chronic migraine.
detection of NeuroDegeneration): Monocenter longitudinal An international, multicentre, non-interventional,
observational study on individuals at high risk for PD to prospective study of treatment with botulinum toxin
determine the value of risk, prodromal and progression A injections in patients with chronic migraine
markers in the prodromal phase. Investigators: Dr. Katerina Freitag, Prof. Dr. Thomas Gasser
Please see also: http://www.trend-studie.de/english/
Investigators: Prof. Dr. Daniela Berg, Prof. Dr. Walter Mätzler ETAM: Validierungsstudie des Erlangen Test of Activities of
(UKSH, Campus Kiel, Neurology), Dr. Kathrin Brockmann, Daily Living in Persons with Mild Dementia or Mild Cogniti-
(UKT, Neurology), Prof. Dr. Andreas Fallgatter, Prof. Dr. ve Impairment (ETAM) bei Parkinson Patienten mit leichten
Gerhard Eschweiler, Prof. Dr. Florian Metzger (UKT, Psychiatry) kognitiven Einschränkungen
Investigators: PD Dr. Inga Liepelt-Scarfone, Patricia Sulzer
iMed-Study: a DZNE-funded project to understand
the relation of Parkinson‘s disease and metabolic profiles Klinische Charakterisierung der Parkinson Demenz:
including diabetes. detaillierte Beschreibung und Identifikation von PDD Sub-
Investigators: Dr. Kathrin Brockmann, Prof. Dr. Thomas Gasser gruppen aufgrund des kognitiven, genetischen, motori-
schen und nicht-motorischem klinischen Profils und deren
MIGAP: (Markers in GBA-associated PD) multicenter study Progression der Erkrankung über einen Verlauf von zwei
of the DZNE to detect biomarkers and protective factors in Jahren
GBA-associated PD. Investigators: PD Dr. Inga Liepelt-Scarfone, Sara Becker,
Investigators: Dr. Kathrin Brockmann, Prof. Dr. Thomas Gasser Patricia Sulzer
PDdementia: A BMBF-funded study to assess Biomarkers ACT14820-MOVES-PD: Multizentrische, randomisierte,
for dementia in PD using Cell Models and human CSF doppelblinde, placebokontrollierte Studie zur Beurteilung
Investigators: Dr. Kathrin Brockmann, Prof. Dr. Thomas Gasser der Wirksamkeit, Sicherheit, Pharmakokinetik und Pharma-
kodynamik von GZ/SAR402671 bei Patienten mit Morbus
Aspen - 1: A Phase 3, Randomized, Double-Blind, Placebo- Parkinson im Frühstadium, die eine GBA-Mutation oder
Controlled, Paralell Group, Multi-Center Trial to Evaluate eine vorspezifizierte Variante tragen
the Efficacy and Safety of a Single Treatment of Daxibotu- Investigators: Dr. Kathrin Brockmann,
linumtoxin A for Injection in Adults with Isolated Cervical PD Dr. Inga Liepelt-Scarfone, Prof. Dr. Thomas Gasser
Dystonia
Investigator: Dr. Ebba Lohmann EPI589-15-002: A phase 2A Safety and Biomarker Study of
EPI-589 in Mitochondrial Subtype and Idiophatic Parkins-
Aspen – OLS: A Phase 3, Open-Label, Multi-Center Trial on‘s Disease Subjects
to Evaluate the Long-Term Safety and Efficacy of Repeat Investigators: Prof. Dr. Thomas Gasser, Dr. Kathrin Brockmann,
Treatments of Daxibotulinumtoxin A for Injection in PD Dr. Inga Liepelt-Scarfone
Adults with Isolated Cervical Dystonia
Investigators: Dr. Ebba Lohmann EarlyStim – 10 year post study follow up: The effect of deep
brain stimulation of the subthalamic nucleus (STN-DBS) on
A 94-52120-174: An international, multicenter, non- quality of life in comparison to best medical treatment in
interventional, prospective, longitudinal study to investigate patients with complicated Parkinson’s disease and pre-
the effectiveness of botulinum toxin A (Dysport®) injections served psychosocial competence.
in patients suffering from post-stroke arm spasticity with Investigators: Prof. Dr. Daniel Weiß
respect to early, medium or late start of treatment.
Investigators: Dr. Katerina Freitag, Prof. Dr. Thomas Gasser Health-related quality of life in LCIG-treated and LCIG-
amenable patients with continued oral dopaminergic
therapy: Non-interventional, multicentre observational trial
for levodopa-carbidopa gel (LCIG) in Germany – BALANCE
Investigator: Prof. Dr. Daniel Weiß
27Department of Neurodegenerative Diseases
Clinical Studies PROSPAX: an integrated multimodal progression chart in
spastic ataxias.
Investigators: Prof. Dr. Matthis Synofzik, PD Dr. Rebecca
Subthalamic steering for therapy optimization in Schüle
Parkinson’s disease (SANTOP)
Investigator: Prof. Dr. Daniel Weiß European Friedreich’s Ataxia Consortium for Translational
Studies (EFACTS)
Lateral steering of nigral stimulation for freezing of gait Investigators: Prof. Dr. Ludger Schöls, Dr. Jennifer Just,
in Parkinson’s disease (NIGRASTEER) Dr. Stefanie Hayer, Prof. Dr. Jörg B. Schulz (Aachen)
Investigator: Prof. Dr. Daniel Weiß
ESMI: European Spinocerebellar Ataxia Type 3 /
Restitution of oral transport, deglutition, and aspiration Machado-Joseph Disease Initiative
with nigral stimulation in Parkinson’s disease? Investigators: Prof. Dr. Ludger Schöls,
Investigator: Prof. Dr. Daniel Weiß Prof. Dr. Matthis Synofzik, Dr. Winfried Ilg
Combined stimulation of STN and SNr for Resistant Sporadic ataxia with adult onset: Natural history study
Freezing of Gait in Parkinson’s disease (SPORTAX)
Investigators: Prof. Dr. Daniel Weiß, Prof. Dr. Alireza Investigators: Prof. Dr. Ludger Schöls,
Gharabaghi, Prof. Dr. Rejko Krüger, Dr. Georgios Naros Prof. Dr. Matthis Synofzik,
Prof. Dr. Thomas Klockgether (Bonn)
Sensing of oscillatory subthalamic nucleus field potentials
for freezing of gait in Parkinson’s disease (SenseFOG) Early onset ataxia: Genetic basis and natural history (EOA)
Investigators: Prof. Dr. Daniel Weiß, Investigators: Prof. Dr. Matthis Synofzik,
Prof. Dr. Alireza Gharabaghi Prof. Dr. Ludger Schöls
Physiotherapie bei Hereditärer Spastischer Spinalparalyse Solving the unsolved Rare Diseases (Solve RD)
(HSP) Investigators: PD Dr. Rebecca Schüle,
Investigators: PD Dr. Rebecca Schüle, Dr. Tim Rattay, Prof. Dr. Matthis Synofzik, Prof. Dr. Ludger Schöls
Prof. Dr. Ludger Schöls
Detecting PreAtaxia: A mixed challenge strategy to
Natural history in Hereditary Spastic Paraplegia identify ataxia at its preclinical stage
(HSP registry) Investigators: Prof. Dr. Matthis Synofzik, Dr. Winfried Ilg
Investigators: PD Dr. Rebecca Schüle, Dr. Sarah Wiethoff,
Prof. Dr. Ludger Schöls SPEECH-Atax: A randomised delayed entry trial of intensive
home-based speech therapy in spinocerebellar ataxias
Phenotype, Genotype and Biomarkers in ALS and Related Investigators: Prof. Dr. Matthis Synofzik, Dr. Adam Vogel
Disorders (Clinical Research in ALS and Related Disorders (University of Melbourne)
for Therapeutic Development Consortium / CReATe)
Investigators: PD Dr. Rebecca Schüle, Slowing down disease progression in premanifest SCA:
PD Dr. Inga Liepelt-Scarfone, Prof. Dr. Matthis Synofzik, a piloting interventional exergame trial (SlowSCA)
Dr. Christoph Kessler, Dr. Carlo Wilke Investigators: Prof. Dr. Matthis Synofzik, Dr. Winfried Ilg
Neuropsychological deficits in genetically defined subtypes Alkahest AKST4290-21: A Randomized, Double-Blind, Pla-
of Hereditary Spastic Paraplegia (HSP) cebo-Controlled Study to Evaluate the Efficacy and Safety
Investigators: PD Dr. Rebecca Schüle, PD Dr. Inga Liepelt of AKST4290 in Subjects with Parkinson’s Disease on Stable
Dopaminergic Treatment
Biomarkers of axonal degeneration in Hereditary Spastic Investigators: Dr. Kathrin Brockmann,
Paraplegia and related diseases PD Dr. Inga Liepelt-Scarfone, Prof. Dr. Thomas Gasser
Investigators: PD Dr. Rebecca Schüle, Dr. Christoph Kessler
28Sie können auch lesen
